Open AccessP709: CLINICAL OUTCOME OF ASCIMINIB TREATMENT IN A REAL‐WORLD MULTI‐RESISTANT CML PATIENT POPULATION.
Author(s) -
Kockerols C. C.,
Janssen J. J.,
Blijlevens N. M.,
Klein S. K.,
HussenDaenen L. G.,
Gorkom G. N.,
Smit W. M.,
Balen P.,
Biemond B. J.,
Cruijsen M. J.,
Corsten M. F.,
Boekhorst P. A.,
Koene H. R.,
Sluis G. L.,
Cornelissen J. J.,
Westerweel P. E.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000845720.69342.77
Subject(s) - medicine , bosutinib , discontinuation , nilotinib , ponatinib , cumulative incidence , clinical trial , population , transplantation , oncology , pediatrics , imatinib , myeloid leukemia , environmental health